Navigation Links
Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements
Date:6/2/2008

or 10 μM AP 12009 in recurrent or refractory anaplastic astrocytoma, with up to 42% at 14 months. At the same time, the initial 25%-overall response rate in the control group fell to zero.

An international, randomized, active-controlled, Phase III study to evaluate the efficacy and safety of AP 12009 as monotherapy in adult patients with recurrent or refractory anaplastic astrocytoma will start in Q3 2008. The study drug will be compared to standard chemotherapy with either Temozolomide or BCNU. Antisense Pharma plans to conduct an interim analysis using the progression rate at 14 months as the surrogate endpoint. Positive results will allow submission for conditional approval by the EMEA. The SAWP at the EMEA indicated that, due to the rarity of the disease, the surrogate endpoint would be accepted, provided that the response data are supported by survival data. The fixed timepoint analysis at 24 months will be acceptable as the primary endpoint for full approval. Furthermore, a time-to-event analysis will be performed. "We are very pleased with this explicit statement by the Scientific Advice Working Party to proceed as we have planned. We sincerely hope that this will accelerate access to treatment for patients in need," says Dr. Hubert Heinrichs, Chief Medical Officer of Antisense Pharma. The Phase III study aims to enroll recurrent or refractory anaplastic astrocytoma patients in about 50 centers in 12 countries.

In the international randomized, active-controlled Phase IIb study, reported at ASCO, recurrent or refractory glioblastoma patients also showed long-lasting tumor responses in the AP 12009 groups (2). As of April 2008 the odds ratio for 10 μM AP 12009 versus control is 0.54. The risk to die is thus reduced by approximately 50% for glioblastoma patients receiving the study drug, as compared to patients under standard chemotherapy treatment. "Based on these data, a pivotal clinical trial in glioblastoma patients with good prognosis, for e
'/>"/>

SOURCE Antisense Pharma GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
4. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
5. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
6. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
7. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
8. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
9. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
10. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
11. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused ... call on Thursday, August 14, 2014, at 4:30 p.m. Eastern ... 30, 2014. Financial results will be issued in a press ... and CEO James LaFrance will host the call, ... Thursday, August 14, 2014 Time: 4:30 p.m. Eastern time (3:30 ...
(Date:7/31/2014)... July 31, 2014 TB Alliance, a ... better, faster and affordable treatments, announced the appointment ... President, External Affairs. Mr. Brock comes to TB ... Major Donor Relations for WWF International (formerly known ... Mr. Brock will guide the TB Alliance,s resource ...
(Date:7/31/2014)... Cryoport, Inc. (OTCBB: CYRX) today announced financial results for ... Recent Operating Highlights , Achieved 92% ... period ended June 30, 2014 compared to the prior ... expand Cryoport,s global reach using the ,powered by Cryoport ... an immunotherapy and vaccine development services company, to support ...
Breaking Medicine Technology:Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 2Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 3Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 4Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 5Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 6Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 7Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 8
... Minn., May 1, 2012  Angeion Corporation (NASDAQ: ... Margolies as Executive Vice President – Global Sales effective ... leading all aspects of the company,s worldwide sales organization ... goals consistent with Angeion,s corporate strategy.  Mr. Margolies will ...
... Total quarterly revenues of $691 million, increased 23 percent versus ... Qualitest revenue growth of 8 percent.  , ... , Reported quarterly diluted loss per share ... , Management expects return to year-over-year adjusted diluted ...
Cached Medicine Technology:Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales 2Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales 3Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales 4Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel 2Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel 3Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel 4Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel 5Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel 6Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel 7Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel 8Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel 9Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel 10Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel 11Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel 12Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel 13Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel 14Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel 15
(Date:7/31/2014)... Women over the age of 65 face numerous barriers ... struggles against poverty and higher rates of asthma with ... issue of Annals of Allergy, Asthma and Immunology ... Allergy, Asthma and Immunology (ACAAI), outlines the challenges faced ... solutions to improve their care. , "Allergists ...
(Date:7/31/2014)... 2014 The 2013 PolyU TSI ... points from 75.07 in 2012. The index measures ... and integrates them into an overall index. The ... more satisfied with Hong Kong over time. , ... in service performance in Hong Kong are attractions ...
(Date:7/31/2014)... 2014 Ce-Classes.com has announced that they ... healthcare professionals, a Systematic Review of Sexual Satisfaction ... in the International Journal of Clinical and Health Psychology. ... to a need to have accurate information about sexual ... treatment possible. The material provides a systematic review ...
(Date:7/31/2014)... GA (PRWEB) July 31, 2014 In today’s ... increasingly difficult to get. Snoring and sleep apnea (a medical ... rob people and their bed partners of the rest they ... 45% of the population snores and 20 million people in ... 10% have been diagnosed and treated; and of those treated, ...
(Date:7/31/2014)... Weblify has finally been released by marketing and advertising ... The result is a perfected and fine tuned platform ... minutes without knowing any HTML or other programming languages. , ... SEO expert, agrees that this platform allows anyone to create ... web site builders out there, but this is truly unique. ...
Breaking Medicine News(10 mins):Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 2Health News:Weblify Review Exposes Ricky Mataka And His New Site Building Platform 3
... , WEDNESDAY, Oct. 13 (HealthDay News) -- Hispanics in the ... by almost eight years, according to a new report. ... Control and Prevention on Wednesday, confirms the so-called "Hispanic paradox" ... live longer than others. "We have known ...
... 2010 Nutrition rating systems and symbols on the ... shoppers if they highlighted four nutrients of greatest concern ... says a new report from the Institute of Medicine. ... most strongly with diet-related health problems affecting many Americans, ...
... (DBS) has proven to be a lifeline for some ... that can cause lack of control over movement, poor ... The procedure is used only for patients ... neurosurgeon uses magnetic resonance imaging or computed tomography to ...
... experience changes in sexual function that leave them feeling ... at the 35th Congress of the European Society for ... that these sexuality and fertility concerns are often not ... from Flinders Medical Centre in Adelaide said that fertility ...
... J. Marc Overhage, M.D., Ph.D., a national leader in ... health information exchange, has been elected to the prestigious ... Dr. Overhage is at the forefront of ... and exchange of medical data to improve patient care ...
... (XMRV) has been the subject of many studies since ... an unclear picture of XMRV,s role in human disease. ... issue of The Journal of Infectious Diseases , ... between XMRV and prostate cancer but not other links ...
Cached Medicine News:Health News:U.S. Hispanics Outlive General Population: CDC 2Health News:U.S. Hispanics Outlive General Population: CDC 3Health News:Nutrition rating enhancing front-of-package nutrition rating systems and symbols: Phase 1 2Health News:Researchers reach consensus on use of deep brain stimulation to treat Parkinson's 2Health News:Fertility concerns of cancer survivors inadequately addressed, study finds 2Health News:Fertility concerns of cancer survivors inadequately addressed, study finds 3Health News:J. Marc Overhage elected to Institute of Medicine 2Health News:New studies examine links between XMRV and human disease 2Health News:New studies examine links between XMRV and human disease 3
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... We offer a complete line ... laboratorians state-of-the-art monoclonal and monoclonal/polyclonal ... detection of enteric pathogens in ... products for Clostridium difficile, Entamoeba ...
... Tox A/B II is a second-generation rapid ELISA ... and B in fecal specimens. The test utilizes ... detecting not only the more common toxin A+ ... It's easy to perform, produces no indeterminates and ...
Medicine Products: